A Single-arm, Single-center Phase II Clinical Study of SBRT Combined with Aparlimab and Platinum-based Doublet Induction Therapy Followed by Concurrent Chemoradiotherapy plus Aparlimab Consolidation Therapy as First-line Treatment for Limited-stage Small Cell Lung Cancer

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 15cd7c4f848cf3d2dcb0f73ffef0cceb59ce6762
First added on: Oct 10, 2026